Zeke Capital Advisors LLC bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,341 shares of the medical research company’s stock, valued at approximately $256,000.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Edwards Lifesciences by 2.0% during the second quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock worth $2,453,311,000 after purchasing an additional 406,901 shares in the last quarter. BlackRock Inc. increased its position in shares of Edwards Lifesciences by 0.8% in the 2nd quarter. BlackRock Inc. now owns 14,109,514 shares of the medical research company’s stock valued at $1,668,309,000 after acquiring an additional 105,819 shares during the period. Bank of New York Mellon Corp increased its position in shares of Edwards Lifesciences by 161.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock valued at $627,207,000 after acquiring an additional 3,277,726 shares during the period. American Century Companies Inc. increased its position in shares of Edwards Lifesciences by 7.0% in the 3rd quarter. American Century Companies Inc. now owns 2,224,010 shares of the medical research company’s stock valued at $243,107,000 after acquiring an additional 144,701 shares during the period. Finally, Wells Fargo & Company MN increased its position in shares of Edwards Lifesciences by 13.3% in the 2nd quarter. Wells Fargo & Company MN now owns 2,119,260 shares of the medical research company’s stock valued at $250,581,000 after acquiring an additional 248,293 shares during the period. Institutional investors own 81.63% of the company’s stock.

Edwards Lifesciences Corporation (NYSE EW) traded up $0.59 during mid-day trading on Monday, hitting $117.00. 251,041 shares of the stock traded hands, compared to its average volume of 1,637,781. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49. Edwards Lifesciences Corporation has a twelve month low of $81.25 and a twelve month high of $121.45. The stock has a market cap of $24,634.67, a price-to-earnings ratio of 32.25, a P/E/G ratio of 2.09 and a beta of 0.51.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.86 by ($0.02). Edwards Lifesciences had a return on equity of 27.22% and a net margin of 22.47%. The firm had revenue of $821.50 million for the quarter, compared to analysts’ expectations of $833.85 million. During the same period in the previous year, the company earned $0.68 earnings per share. The company’s revenue was up 11.1% compared to the same quarter last year. research analysts expect that Edwards Lifesciences Corporation will post 3.75 EPS for the current year.

In other Edwards Lifesciences news, VP Larry L. Wood sold 18,960 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $108.54, for a total value of $2,057,918.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $116.45, for a total transaction of $617,185.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 172,480 shares of company stock worth $18,548,810. Corporate insiders own 2.13% of the company’s stock.

EW has been the topic of several research reports. Canaccord Genuity reissued a “buy” rating and issued a $135.00 target price (down from $155.00) on shares of Edwards Lifesciences in a research report on Wednesday, October 25th. BMO Capital Markets reissued a “buy” rating and issued a $132.00 target price on shares of Edwards Lifesciences in a research report on Friday, September 1st. William Blair reissued an “outperform” rating on shares of Edwards Lifesciences in a research report on Monday, August 28th. SunTrust Banks set a $124.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Finally, Morgan Stanley cut their target price on Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating on the stock in a research report on Thursday, October 26th. Seven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $125.53.

COPYRIGHT VIOLATION NOTICE: “Zeke Capital Advisors LLC Invests $256,000 in Edwards Lifesciences Corporation (EW) Stock” was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/zeke-capital-advisors-llc-invests-256000-in-edwards-lifesciences-corporation-ew-stock/1743149.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.